DeepNewz, mobile.

People-sourced. AI-powered. Unbiased News.

Screenshot of DeepNewz app showing story detail view.

Screenshot of DeepNewz app showing story list view.

Search

For You

Apellis News

Footer

AI

AI Fundraising
AI Modeling
AI Products

Business

Automobile
Company Earnings
Economics
Law
Prediction Markets
Real Estate
Rumors
Stocks
VC

Crypto

Airdrops
Blockchains
CBDCs
DeFi
Hacks
Markets
Memecoin
Mining
NFT
Regulation

Culture

Anime
Celebrities
Crime
Education
Movies
Music
Obituary
TV
Video Games

Environment

Climate
Energy
Natural Disasters
Natural Resources
Sustainability

Politics

DOGE
Epstein Files
Executive Orders
Tariffs
US Domestic Policy
US Elections
US Foreign Policy
US Gov Appointments
US Judiciary
US Legislation
War

Science

Archeology
Bio
Health
Math
Pharma
Physics
Space

Sports

Boxing
Chess
Cricket
Golf
Hockey
MLB
NBA
NCAA
NFL
Olympics
PGA
Poker
Racing
Rugby
Soccer
Tennis
UFC

Tech

AR-VR
Fintech
Infosec
IoT
Metaverse
Policy
Robotics
Smart Home
Software
Startups
Wearables

United States

Arizona
Boston
California
Chicago
Colorado
Detroit
Florida
Georgia
Las Vegas
Los Angeles
New Jersey
New Mexico
New York
Ohio
Oregon
Philadelphia
San Francisco
Seattle
Texas
Utah
Washington DC

World

Terms of Service

WhatsApp YouTube X

© 2025 DeepNFTValue, Inc. All rights reserved.

Top stories

FDA Approves Apellis’ EMPAVELI for Rare Kidney Diseases in Patients 12+, Showing 68% Proteinuria Reduction; Q2 Revenue $178M

Company Earnings

FDA Approves Apellis’ EMPAVELI for Rare Kidney Diseases in Patients 12+, Showing 68% Proteinuria Reduction; Q2 Revenue $178M

Authors

9

2 days ago

Latest stories

Latest stories

Jul 31, 2025
Jul 31, 2025
Company Earnings
Pharma
Business
FDA Approves Apellis’ EMPAVELI for Rare Kidney Diseases in Patients 12+, Showing 68% Proteinuria Reduction; Q2 Revenue $178M
Authors
9
2 days ago

Previous
Next

Join our channels

Get the latest stories live on any device.

WhatsApp
Top Stories
Join
Telegram
Top Stories
Join